Related Experiment Video
Updated: Jun 20, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Managing pediatric hepatitis C: current and emerging treatment options
Wikrom Karnsakul1, Mary Kay Alford, Kathleen B Schwarz
1Pediatric Liver Center, Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Therapeutics and Clinical Risk Management
|August 27, 2009
Summary
Hepatitis C (HCV) in children is primarily transmitted from mother to child. While interferon therapy shows promise, new antiviral drugs are being developed to improve sustained virological response (SVR) and manage liver disease progression.
Area of Science:
- Pediatric Infectious Diseases
- Hepatology
- Virology
Background:
- Maternal-fetal transmission is the primary route for pediatric Hepatitis C Virus (HCV) infection since 1992.
- Chronic HCV infection (CHC) in children can lead to progressive liver pathology, including fibrosis, cirrhosis, and hepatocellular carcinoma in adolescents.
- Sustained virological response (SVR), defined by undetectable HCV RNA, is the primary goal of antiviral therapy.
Purpose of the Study:
- To review recent advancements in the therapy of CHC in children.
- To discuss the clinical development of emerging antiviral drugs for pediatric HCV treatment.
Main Methods:
- Review of current literature on pediatric HCV treatment.
- Analysis of clinical trial data for new antiviral agents in children.
Main Results:
- Interferon-based therapy demonstrates higher efficacy in young children compared to adults with CHC.
- Emerging direct-acting antiviral drugs show potential for improved SVR rates and safety profiles in pediatric populations.
Conclusions:
- Current treatment strategies are evolving, with interferon therapy being effective in children.
- New antiviral drugs are under development, offering hope for more effective and safer treatment options for pediatric HCV infection.
- Early diagnosis and treatment are crucial to prevent long-term liver complications in children with HCV.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...